Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

Matrix Assisted Laser Desorption/Ionization Mass Spectrometry Imaging (MALDI MSI) for Monitoring of Drug Response in Primary Cancer Spheroids.

Mittal P, Price ZK, Lokman NA, Ricciardelli C, Oehler MK, Klingler-Hoffmann M, Hoffmann P.

Proteomics. 2019 Aug 31:e1900146. doi: 10.1002/pmic.201900146. [Epub ahead of print] No abstract available.

PMID:
31474002
2.

4-Methylumbelliferone Inhibits Cancer Stem Cell Activation and Overcomes Chemoresistance in Ovarian Cancer.

Lokman NA, Price ZK, Hawkins EK, Macpherson AM, Oehler MK, Ricciardelli C.

Cancers (Basel). 2019 Aug 15;11(8). pii: E1187. doi: 10.3390/cancers11081187.

3.

Targeting CDK9 for treatment of colorectal cancer.

Rahaman MH, Lam F, Zhong L, Teo T, Adams J, Yu M, Milne RW, Pepper C, Lokman NA, Ricciardelli C, Oehler MK, Wang S.

Mol Oncol. 2019 Aug 9. doi: 10.1002/1878-0261.12559. [Epub ahead of print]

4.

Anti-tumour effects of all-trans retinoid acid on serous ovarian cancer.

Lokman NA, Ho R, Gunasegaran K, Bonner WM, Oehler MK, Ricciardelli C.

J Exp Clin Cancer Res. 2019 Jan 8;38(1):10. doi: 10.1186/s13046-018-1017-7.

5.

S100A10 and Cancer Hallmarks: Structure, Functions, and its Emerging Role in Ovarian Cancer.

Noye TM, Lokman NA, Oehler MK, Ricciardelli C.

Int J Mol Sci. 2018 Dec 19;19(12). pii: E4122. doi: 10.3390/ijms19124122. Review.

6.

Differing Roles of Hyaluronan Molecular Weight on Cancer Cell Behavior and Chemotherapy Resistance.

Price ZK, Lokman NA, Ricciardelli C.

Cancers (Basel). 2018 Dec 3;10(12). pii: E482. doi: 10.3390/cancers10120482. Review.

7.

Novel ex vivo ovarian cancer tissue explant assay for prediction of chemosensitivity and response to novel therapeutics.

Ricciardelli C, Lokman NA, Sabit I, Gunasegaran K, Bonner WM, Pyragius CE, Macpherson AM, Oehler MK.

Cancer Lett. 2018 May 1;421:51-58. doi: 10.1016/j.canlet.2018.02.006. Epub 2018 Feb 6.

PMID:
29425684
8.

Mass Spectrometry Analyses of Multicellular Tumor Spheroids.

Acland M, Mittal P, Lokman NA, Klingler-Hoffmann M, Oehler MK, Hoffmann P.

Proteomics Clin Appl. 2018 May;12(3):e1700124. doi: 10.1002/prca.201700124. Epub 2018 Feb 9. Review.

PMID:
29227035
9.

CIB2 Negatively Regulates Oncogenic Signaling in Ovarian Cancer via Sphingosine Kinase 1.

Zhu W, Jarman KE, Lokman NA, Neubauer HA, Davies LT, Gliddon BL, Taing H, Moretti PAB, Oehler MK, Pitman MR, Pitson SM.

Cancer Res. 2017 Sep 15;77(18):4823-4834. doi: 10.1158/0008-5472.CAN-17-0025. Epub 2017 Jul 20.

10.

Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.

Ricciardelli C, Lokman NA, Pyragius CE, Ween MP, Macpherson AM, Ruszkiewicz A, Hoffmann P, Oehler MK.

Oncotarget. 2017 Mar 14;8(11):17819-17832. doi: 10.18632/oncotarget.14867.

11.

MicroRNA-194 Promotes Prostate Cancer Metastasis by Inhibiting SOCS2.

Das R, Gregory PA, Fernandes RC, Denis I, Wang Q, Townley SL, Zhao SG, Hanson AR, Pickering MA, Armstrong HK, Lokman NA, Ebrahimie E, Davicioni E, Jenkins RB, Karnes RJ, Ross AE, Den RB, Klein EA, Chi KN, Ramshaw HS, Williams ED, Zoubeidi A, Goodall GJ, Feng FY, Butler LM, Tilley WD, Selth LA.

Cancer Res. 2017 Feb 15;77(4):1021-1034. doi: 10.1158/0008-5472.CAN-16-2529. Epub 2016 Dec 23.

12.

Novel IEF Peptide Fractionation Method Reveals a Detailed Profile of N-Terminal Acetylation in Chemotherapy-Responsive and -Resistant Ovarian Cancer Cells.

Weiland F, Arentz G, Klingler-Hoffmann M, McCarthy P, Lokman NA, Kaur G, Oehler MK, Hoffmann P.

J Proteome Res. 2016 Nov 4;15(11):4073-4081. Epub 2016 Sep 19.

PMID:
27569743
13.

MALDI Mass Spectrometry Imaging Reveals Decreased CK5 Levels in Vulvar Squamous Cell Carcinomas Compared to the Precursor Lesion Differentiated Vulvar Intraepithelial Neoplasia.

Zhang C, Arentz G, Winderbaum L, Lokman NA, Klingler-Hoffmann M, Mittal P, Carter C, Oehler MK, Hoffmann P.

Int J Mol Sci. 2016 Jul 8;17(7). pii: E1088. doi: 10.3390/ijms17071088.

14.

Lymph node metastasis of primary endometrial cancers: Associated proteins revealed by MALDI imaging.

Mittal P, Klingler-Hoffmann M, Arentz G, Winderbaum L, Lokman NA, Zhang C, Anderson L, Scurry J, Leung Y, Stewart CJ, Carter J, Kaur G, Oehler MK, Hoffmann P.

Proteomics. 2016 Jun;16(11-12):1793-801. doi: 10.1002/pmic.201500455. Epub 2016 May 10.

PMID:
27061135
15.

Annexin A2 and S100A10 are independent predictors of serous ovarian cancer outcome.

Lokman NA, Pyragius CE, Ruszkiewicz A, Oehler MK, Ricciardelli C.

Transl Res. 2016 May;171:83-95.e1-2. doi: 10.1016/j.trsl.2016.02.002. Epub 2016 Feb 10.

PMID:
26925708
16.

Transketolase is upregulated in metastatic peritoneal implants and promotes ovarian cancer cell proliferation.

Ricciardelli C, Lokman NA, Cheruvu S, Tan IA, Ween MP, Pyragius CE, Ruszkiewicz A, Hoffmann P, Oehler MK.

Clin Exp Metastasis. 2015 Jun;32(5):441-55. doi: 10.1007/s10585-015-9718-1. Epub 2015 Apr 21.

PMID:
25895698
17.

Chemotherapy-induced hyaluronan production: a novel chemoresistance mechanism in ovarian cancer.

Ricciardelli C, Ween MP, Lokman NA, Tan IA, Pyragius CE, Oehler MK.

BMC Cancer. 2013 Oct 14;13:476. doi: 10.1186/1471-2407-13-476.

18.

Annexin A2 is regulated by ovarian cancer-peritoneal cell interactions and promotes metastasis.

Lokman NA, Elder AS, Ween MP, Pyragius CE, Hoffmann P, Oehler MK, Ricciardelli C.

Oncotarget. 2013 Aug;4(8):1199-211.

19.

Chick chorioallantoic membrane (CAM) assay as an in vivo model to study the effect of newly identified molecules on ovarian cancer invasion and metastasis.

Lokman NA, Elder AS, Ricciardelli C, Oehler MK.

Int J Mol Sci. 2012;13(8):9959-70. doi: 10.3390/ijms13089959. Epub 2012 Aug 10.

20.

The role of annexin A2 in tumorigenesis and cancer progression.

Lokman NA, Ween MP, Oehler MK, Ricciardelli C.

Cancer Microenviron. 2011 Aug;4(2):199-208. doi: 10.1007/s12307-011-0064-9. Epub 2011 Mar 5.

Supplemental Content

Loading ...
Support Center